Upadacitinib Shows Strong Efficacy in Phase 3 Alopecia Areata Trial
The trial is one of 2 phase 3 studies of upadacitinib in patients with severe alopecia areata.
Previous Post
Advances in MS Therapies Reshape the Treatment Landscape
Next Post
Guselkumab is safe and effective in patients with moderate-to-severe Crohn’s disease
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago